138 results on '"Rowe, S."'
Search Results
2. 312 Validation of a novel integrated image guided potential difference system to facilitate conduct of lower airway potential difference
3. 271 Synergistic effects on readthrough of G542X CFTR by combining eRF1 and eRF3 degraders
4. 229 Glutathione and bicarbonate nanoparticles improve mucociliary transport in cystic fibrosis epithelia
5. 579 Lipid concentrations after 12 to 18 months of clinically prescribed elexacaftor tezacaftor ivacaftor—PROMISE substudy
6. 141 Factors associated with significantly corrected sweat chloride in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor—results from the PROMISE and RECOVER studies
7. 113 Effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in people with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: The SIMPLIFY-MCC Study
8. 131 In vitro responses of F508DEL human nasal epithelial cells correlate with clinical improvement with elexacaftor-tezacaftor-ivacaftor
9. 528 Alterations in the fecal microbiota of patients with advanced cystic fibrosis–associated liver disease after 6 months of elexacaftortezacaftor-ivacaftor
10. 295 CFTR-R933 mutations reduce channel opening but still permit potentiation by ivacaftor
11. 318 Novel eRF3 degrader monotherapy induces translational readthrough of CFTR nonsense mutations at therapeutically relevant levels
12. 191 Development and initial evaluation of a platform to measure in vivo short circuit current to detect CFTR functional restoration
13. 47 Novel detection and infection modeling of Aspergillus fumigatus in pyocyanin-stimulated primary airway epithelium and mucus models
14. 268 Identifying the amino acid(s) inserted upon premature termination codon readthrough and their effect on CFTR functionality
15. 64 Sputum density of Aspergillus fumigatus markedly declines after treatment with elexacaftor-tezacaftor-ivacaftor
16. 613 Understanding synergy in nonsense suppression therapy for cystic fibrosis transmembrane conductance regulator nonsense mutations
17. 610 Evaluating the mechanism of amino acid insertion upon readthrough of cystic fibrosis transmembrane conductance regulator nonsense mutations
18. 15 Promise: Glucose excursion and insulin secretion after 12 to 18 months of highly effective modulator therapy
19. 572 Changes in total immunoglobulin E levels and fungal acquisition in people with cystic fibrosis before and after elexacaftor/tezacaftor/ivacaftor initiation
20. 155 Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis
21. 691 Synthetic aminoglycoside ELX-02 induces readthrough of cystic fibrosis transmembrane conductance regulator–G550X, producing super-functional protein that can be further enhanced by cystic fibrosis transmembrane conductance regulator correctors
22. 661 The PDE4 inhibitor apremilast enhances benefits of cystic fibrosis transmembrane conductance regulator modulators in vitro and in vivo
23. 113 Development and characterization of pulmonary disease in G551D ferret model on chest computed tomography imaging
24. 154 In vitro responses of F508DEL human nasal epithelial cells correlate with clinical improvement with elexacaftor/tezacaftor/ivacaftor
25. 410 Hypoxia-induced cystic fibrosis transmembrane conductance regulator dysfunction is a universal mechanism underlying reduced mucociliary transport in sinusitis
26. 173 Effectiveness of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis: The pediatric PROMISE study
27. 137 Tobacco smoke exposure reduces the clinical efficacy of ivacaftor: Results from the G551D Observational Trial
28. 485: Nitric oxide produced during Pseudomonas aeruginosa denitrification increases tobramycin killing of tolerant cells
29. 671: Generation and characterization of a patient-derived iPSC line carrying the CFTR G542X/G542X mutation
30. 532: Restoration of CFTR-dependent current by readthrough therapy in 2-D organoid monolayers derived from patients with nonsense mutations
31. 544: Safety and tolerability of single and repeat doses of MRT5005, an inhaled CFTR mRNA replacement therapy, in adult CF patients
32. 352: Altered mucin sialylation results in delayed mucociliary transport in CF
33. 429: Effects of elexacaftor/tezacaftor/ivacaftor on the CF sputum microbiome: Preliminary analysis from the Promise study
34. 384: Advances of magnetomotive micro-optical coherence tomography for mucus microrheology
35. 602: Antisense oligonucleotide target site blockade of miR-145 binding selectively enhances CFTR correction in airway epithelial cells and nasal organoids
36. 216: Nutritional and metabolic effects of elexacaftor/tezacaftor/ivacaftor in adults and adolescents with cystic fibrosis
37. 581: YOR1 modeling of CFTR nonsense variants to discover effects of genetic factors and sequence context on efficacy of PTC suppression
38. 552: New combination readthrough agents and CFTR corrector therapy to improve CFTR function of cystic fibrosis with nonsense mutation
39. 531: Identification of a compound that mediates readthrough of CFTR nonsense mutations by reducing eRF1 levels
40. 445: Adaptation of Pseudomonas aeruginosa isolates from cystic fibrosis patients to the anaerobic environment
41. EPS6.04 Elexacaftor/tezacaftor/ivacaftor (ETI) reduces sputum pathogen density and lung inflammation, but infection and inflammation persist
42. EPS2.08 Clinical effort against smoke exposure in cystic fibrosis (CEASE-CF): feasibility, acceptability, and preliminary efficacy
43. WS13.3 Tobacco smoke exposure limits the benefit of Symdeko® in paediatric cystic fibrosis patients: Cystic Fibrosis Foundation Patient Registry analysis
44. WS06-2 Initial results evaluating the add-on effect of the novel CFTR corrector PTI-801 in cystic fibrosis subjects
45. WS09.1 Development of a CFTR mRNA therapy capable of treating lung disease in all CFTR patients
46. EPS1.3 Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: study design and rationale for the Rio-CF study
47. WS13.1 QR-010, an investigational RNA therapeutic, improves CFTR activity in cystic fibrosis subjects homozygous for the F508del mutation
48. WS13.3 Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)
49. WS7.5 Interim results of the phase 3 open-label study of ataluren in nonsense mutation cystic fibrosis (nmCF)
50. 63 The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.